Einzeltreffer — DigiBib

Objective and Design: The objective of this study was to determine the ability of meloxicam prophylaxis and therapy to blunt the effect of complete Freund's adjuvant (CFA) induced monoarthritis.

Materials and Methods: First the validity of this animal model was established by examining joint changes at multiple levels after injecting CFA into the tibio-tarsal joint. Next, meloxicam (5 mg/kg) or vehicle was administered on days 0-7 (prophylactic) and on days 7-16 (therapeutic) in separate groups of animals.

Results: The CFA-injected joint demonstrated hallmark histological and structural changes such as pannus formation, bone remodeling, cartilage erosion and immune cell infiltration. Both prophylactic and therapeutic treatment with meloxicam effectively reduced swelling (ankle circumference), oedema and extravasation of Evans blue dye in the affected joint. Moreover, meloxicam reduced loss in range of motion and also reduced mechanical stimulus evoked pain scores. Notably, these effects persisted after discontinuing drug treatment.

Conclusion: The present study provides a unique comparison of prophylactic versus therapeutic effects of meloxicam in the CFA-induced model of monoarthritis.

Titel:	Sensory and vascular changes in a rat monoarthritis model: prophylactic and therapeutic effects of meloxicam.
Autor/in / Beteiligte Person:	Hashmi, JA ; Yashpal, K ; Holdsworth, DW ; Henry, JL
Link:	Full Text Finder (Volltext)
Zeitschrift:	Inflammation research : official journal of the European Histamine Research Society ... [et al.], Jg. 59 (2010-08-01), Heft 8, S. 667-78
Veröffentlichung:	Basel, Switzerland : Birkhäuser, c1995-, 2010
Medientyp:	academicJournal
ISSN:	1420-908X (electronic)
DOI:	10.1007/s00011-010-0179-3
Schlagwort:	Animals Freund's Adjuvant adverse effects Humans Male Meloxicam Rats Rats, Sprague-Dawley Tarsus, Animal anatomy & histology Tarsus, Animal pathology Anti-Inflammatory Agents, Non-Steroidal therapeutic use Arthritis, Experimental drug therapy Arthritis, Experimental pathology Arthritis, Experimental physiopathology Cyclooxygenase Inhibitors therapeutic use Inflammation drug therapy Inflammation pathology Inflammation physiopathology Thiazines therapeutic use Thiazoles therapeutic use
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [Inflamm Res] 2010 Aug; Vol. 59 (8), pp. 667-78. <i>Date of Electronic Publication: </i>2010 Mar 28. MeSH Terms: Arthritis, Experimental* / drug therapy ; Arthritis, Experimental* / pathology ; Arthritis, Experimental* / physiopathology ; Inflammation* / drug therapy ; Inflammation* / pathology ; Inflammation* / physiopathology ; Anti-Inflammatory Agents, Non-Steroidal / therapeutic use ; Cyclooxygenase Inhibitors / therapeutic use ; Thiazines / therapeutic use ; Thiazoles / therapeutic use ; Animals ; Freund's Adjuvant / adverse effects ; Humans ; Male ; Meloxicam ; Rats ; Rats, Sprague-Dawley ; Tarsus, Animal / anatomy & histology ; Tarsus, Animal / pathology References: Eur J Neurosci. 2005 Oct;22(8):2005-15. (PMID: 16262639) ; J Chronic Dis. 1963 Aug;16:863-74. (PMID: 14058394) ; J Neurosci. 2004 Jan 21;24(3):642-51. (PMID: 14736850) ; Pharmacol Biochem Behav. 2007 Aug-Sep;87(3):349-59. (PMID: 17583780) ; J Pharmacol Exp Ther. 2003 Aug;306(2):490-7. (PMID: 12730275) ; Inflamm Res. 1997 Jun;46(6):203-10. (PMID: 9243303) ; Pain. 1988 Dec;35(3):299-312. (PMID: 2906425) ; Rheumatology (Oxford). 2003 May;42 Suppl 2:ii17-21. (PMID: 12817091) ; Arthritis Rheum. 2003 Jan;48(1):64-71. (PMID: 12528105) ; Rheumatol Int. 1987;7(4):169-71. (PMID: 3671990) ; Arthritis Rheum. 1980 Feb;23(2):137-45. (PMID: 7362664) ; FEBS Lett. 1996 Jul 22;390(2):165-9. (PMID: 8706851) ; Int Immunopharmacol. 2004 Feb;4(2):299-310. (PMID: 14996421) ; Inflammopharmacology. 2006 Mar;14(1-2):17-21. (PMID: 16835708) ; Scand J Rheumatol. 1991;20(5):326-35. (PMID: 1947895) ; Nurs Res. 2007 Nov-Dec;56(6):434-40. (PMID: 18004190) ; J Rheumatol. 1995 Apr;22(4):733-9. (PMID: 7791173) ; Neuroscience. 2001;102(3):669-79. (PMID: 11226703) ; Anesthesiology. 2002 Jul;97(1):170-6. (PMID: 12131119) ; J Rheumatol. 1987 Jun;14(3):628-31. (PMID: 3625649) ; Pharmacol Biochem Behav. 1988 Oct;31(2):445-51. (PMID: 3244721) ; Arthritis Rheum. 2000 Feb;43(2):386-9. (PMID: 10693879) ; Eur J Pain. 2006 Aug;10(6):537-49. (PMID: 16199187) ; Br J Pharmacol. 1998 Sep;125(2):341-6. (PMID: 9786507) ; Arthritis Rheum. 2007 Dec;56(12):4015-23. (PMID: 18050216) ; J Rheumatol. 2002 Mar;29(3):436-46. (PMID: 11908554) ; Pain. 1987 Feb;28(2):223-238. (PMID: 3822505) ; Inflamm Res. 1995 Oct;44(10):423-33. (PMID: 8564518) ; J Neurosci Methods. 1999 Mar 1;87(2):185-93. (PMID: 11230815) ; Am J Med. 1983 Dec 30;75(6A):16-26. (PMID: 6660237) ; J Neurosci Methods. 1993 Aug;49(1-2):5-10. (PMID: 8271831) ; Eur J Neurosci. 2008 Mar;27(5):1153-65. (PMID: 18364035) ; Clin Exp Rheumatol. 1996 Nov-Dec;14(6):633-41. (PMID: 8978958) ; Transplant Proc. 1999 May;31(3):1590-1. (PMID: 10331013) ; J Rheumatol Suppl. 1996 Mar;44:47-51. (PMID: 8833052) ; Ann Rheum Dis. 2003 Dec;62(12):1178-84. (PMID: 14644855) ; J Neurol Sci. 1984 Jan;63(1):55-61. (PMID: 6699654) ; J Neurosci. 2006 Jan 25;26(4):1281-92. (PMID: 16436616) ; Pharmacoeconomics. 2004;22(2 Suppl 1):1-12. (PMID: 15157000) ; Neuroreport. 2000 Mar 20;11(4):737-41. (PMID: 10757511) ; J Clin Epidemiol. 2000 Sep;53(9):895-907. (PMID: 11004416) ; Behav Brain Res. 1987 Apr;24(1):11-29. (PMID: 3580112) ; Rheumatology (Oxford). 2003 Nov;42 Suppl 3:iii3-10. (PMID: 14585912) ; Arthritis Rheum. 2008 May;58(5):1354-65. (PMID: 18438856) ; J Rheumatol. 1993 Jan;20(1):7-11. (PMID: 8441169) ; Semin Arthritis Rheum. 2000 Apr;29(5):305-20. (PMID: 10805355) ; Ann Rheum Dis. 2003 Nov;62 Suppl 2:ii94-6. (PMID: 14532160) ; J Neurochem. 2001 Apr;77(2):372-82. (PMID: 11299299) ; N Engl J Med. 1996 Mar 28;334(13):835-40. (PMID: 8596551) ; Arthritis Rheum. 1999 Feb;42(2):347-56. (PMID: 10025930) ; Immunol Rev. 2001 Dec;184:184-202. (PMID: 12086312) ; Pain. 1992 Jan;48(1):73-81. (PMID: 1738577) ; Arthritis Rheum. 1978 Sep-Oct;21(7):827-33. (PMID: 100122) ; Br J Rheumatol. 1993 Jan;32(1):31-5. (PMID: 7678534) ; Med Decis Making. 2007 Mar-Apr;27(2):138-50. (PMID: 17409364) ; Neuroscience. 2008 Sep 9;155(4):1227-36. (PMID: 18652880) ; Curr Opin Rheumatol. 2002 Mar;14(2):121-6. (PMID: 11845016) ; Ann Rheum Dis. 2009 Feb;68(2):183-90. (PMID: 18375533) ; Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii84-6. (PMID: 12379632) ; Clin Drug Investig. 2008;28(11):687-95. (PMID: 18840011) ; Arthritis Rheum. 2001 Jun;44(6):1428-37. (PMID: 11407705) ; J Rheumatol. 2007 Jun;34(6):1241-7. (PMID: 17516624) Grant Information: 13460 Canada CAPMC CIHR Substance Nomenclature: 0 (Anti-Inflammatory Agents, Non-Steroidal) ; 0 (Cyclooxygenase Inhibitors) ; 0 (Thiazines) ; 0 (Thiazoles) ; 9007-81-2 (Freund's Adjuvant) ; VG2QF83CGL (Meloxicam) Entry Date(s): Date Created: 20100330 Date Completed: 20101115 Latest Revision: 20211020 Update Code: 20231215 PubMed Central ID: PMC5132625

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Sensory and vascular changes in a rat monoarthritis model: prophylactic and therapeutic effects of meloxicam.